| Name | Title | Contact Details |
|---|
Agiliti is a company of 3,000 passionate equipment management experts who believe every interaction has the power to change a life. We have built a brand thats dedicated to optimizing clinical outcomes while relentlessly improving economic outcomes for our customers. We help hospitals and health systems address their challenges — including compliance requirements, general cost pressures, the rise of consumerism, looming talent shortages and the rising quality issues related to medical devices. We ensure the right equipment is in the right place at the right time — from infusion pumps to beds to imaging devices — so physicians, nurses and other caregivers spend more time focused on patient care. We provide supply chain teams with valuable insights they can use to control costs. And we offer a full range of clinical engineering services — supplemental support and full outsource programs — to unburden your biomed department.
Fallbrook Engineering is a Valley Center, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Longevity secrets from the worlds longest-lived people.
Dental One Partners is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cleveland, OH. To find more information about Dental One Partners, please visit www.dentalonepartners.com
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.